Analyst Price Target is $21.75
▲ +400.00% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Ventyx Biosciences in the last 3 months. The average price target is $21.75, with a high forecast of $62.00 and a low forecast of $5.00. The average price target represents a 400.00% upside from the last price of $4.35.
Current Consensus is
Moderate Buy
The current consensus among 9 polled investment analysts is to moderate buy stock in Ventyx Biosciences. This Moderate Buy consensus rating has held steady for over two years.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Read More